Jillian Dilmore is the Corp. Sec. at Baudax Bio Inc.
Jillian's mailing address filed with the SEC is C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN, PA, 19355.
Over the last 5 years, insiders at Baudax Bio Inc have traded over $0 worth of Baudax Bio Inc stock and bought 301,900 units worth $299,893 . The most active insiders traders include Winston J Churchill, Alfred Altomari y Wayne Weisman. On average, Baudax Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $4,063. The most recent stock trade was executed by Geraldine Henwood on 15 December 2022, trading 1,200 units of BXRX stock currently worth $3,060.
baudax bio, inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed phase iii clinical trials for the management of moderate to severe pain; and is in the phase iiib clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. the company's early-stage product candidates includes rp1000, an intermediate-acting neuromuscular blocking agent (nmba) that is in phase i clinical trial; and rp2000, an ultrashort-acting nmba, which is in pre-clinical trial; and a reversal agent, as well as dex-in, a proprietary intranasal formulation of dexmedetomidine. the company was incorporated in 2019 and is based in malvern, pennsylvania.
Baudax Bio Inc executives and other stock owners filed with the SEC include: